Progressive External Ophthalmoplegia is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox disease}}
Progressive External Ophthalmoplegia (PEO) is a mitochondrial disorder characterized by progressive loss of eye movements, ptosis (drooping eyelids), and often the presence of multiple mitochondrial DNA (mtDNA) deletions in skeletal muscle.
Progressive External Ophthalmoplegia represents one of the most common manifestations of mitochondrial DNA deletion syndromes. The condition is typically adult-onset and progresses gradually over decades, affecting the extraocular muscles responsible for eye movements.
- Prevalence: Approximately 1 in 100,000 individuals
- Age of onset: Typically 18-40 years
- Gender: Affects both males and females equally
- Inheritance: Can be autosomal dominant or sporadic
The most common genetic forms involve mutations in:
| Gene |
Protein |
Inheritance |
Notes |
| TWNK (PEO1) |
Twinkle helicase |
AD |
Most common cause |
| POLG |
DNA polymerase gamma |
AD |
Most common cause |
| POLG2 |
POLG accessory subunit |
AD |
Rare |
| RRM2B |
p53-inducible RRM2B |
AD |
Rare |
| Gene |
Protein |
Notes |
| TK2 |
Thymidine kinase 2 |
mtDNA depletion |
| RRM2B |
RRM2B |
Severe early-onset form |
| OPA1 |
OPA1 |
Plus optic atrophy |
Many cases appear sporadic due to spontaneous mtDNA deletions in somatic cells.
- Large-scale mtDNA deletions: Typically 1-10 kb deletions
- Multiple deletion patterns: Heteroplasmy with deleted and wild-type mtDNA
- Clonal expansion: Deleted mtDNA molecules expand clonally in muscle fibers
- Defective mtDNA replication leads to deletion formation
- Impaired mitochondrial helicase function (TWNK mutations)
- Abnormal polymerase gamma activity (POLG mutations)
- Compromised mitochondrial quality control
- Ragged-red fibers: Accumulation of abnormal mitochondria
- ** cytochrome c oxidase (COX) negative fibers**: Loss of complex IV activity
- Subsarcolemmal mitochondrial accumulation: Seen on muscle biopsy
| Symptom |
Description |
Onset |
| Ophthalmoplegia |
Progressive limitation of eye movements |
Gradual, bilateral |
| Ptosis |
Drooping eyelids |
Often first sign |
| Diplopia |
Double vision |
Less common |
| Reduced eye movements |
Upward gaze first affected |
Progressive |
- Exercise intolerance: Fatigue with minimal exertion
- Myopathy: Proximal muscle weakness
- Sensorineural hearing loss: High-frequency hearing loss
- Cardiac conduction defects: Atrioventricular block
- Endocrine disorders: Diabetes mellitus, hypoparathyroidism
- Cerebellar ataxia: In some cases
| Type |
Features |
| Pure PEO |
Isolated eye movement deficits |
| PEO-plus |
PEO with additional systemic features |
| Kearns-Sayre syndrome |
PEO, cardiac conduction, cerebellar ataxia |
- Neurological examination: Document eye movement limitations
- Ophthalmologic evaluation: Ptosis assessment, visual acuity
- Cardiac evaluation: ECG, Holter monitoring
- Endocrine workup: Blood glucose, thyroid function
- Serum creatine kinase: Often elevated
- Lactate: May be elevated at rest or after exercise
- CSF protein: Often elevated in Kearns-Sayre syndrome
- Gom trichrome staining showing ragged-red fibers
- COX-negative fibers
- Southern blot for mtDNA deletions
- Targeted gene panel for mitochondrial disease
- Whole mtDNA sequencing
- Nuclear gene sequencing (POLG, TWNK, etc.)
- Ophthalmologic interventions: Ptosis surgery if severe
- Cardiac management: Pacemaker for conduction defects
- Hearing aids: For hearing loss
- Physical therapy: For myopathy
| Treatment |
Evidence |
Notes |
| Coenzyme Q10 |
Moderate |
May improve some patients |
| L-carnitine |
Variable |
Supports mitochondrial function |
| Vitamin supplements |
Limited |
B-complex, vitamin E |
| Exercise training |
Beneficial |
Avoid overexertion |
- Annual cardiac evaluation
- Regular ophthalmologic follow-up
- Endocrine screening
- Audiometric testing
- Life expectancy: Generally normal with appropriate management
- Disease progression: Slow, over decades
- Major causes of morbidity: Cardiac complications, disability from ptosis
- Gene therapy: AAV-vector delivery of wild-type genes
- Mitochondrial replacement therapy: Germline and somatic approaches
- Small molecule therapies: Targeting mtDNA maintenance
- iPSC models: Patient-derived cellular models for drug screening
The study of Progressive External Ophthalmoplegia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hirano M, et al. (1995). Mitochondrial genetics. Human Molecular Genetics, 4(spec_no): 1729-1733.
- Zeviani M, et al. (1998). Autosomal dominant progressive external ophthalmoplegia. Brain, 121(Pt 11): 1989-2002.
- Pitceathly RD, et al. (2012). Nuclear genetic mitochondrial disease. Lancet Neurology, 11(11): 960-971.
- Suomalainen A, et al. (2020). Mitochondrial DNA replication disorders. Nature Reviews Disease Primers, 6(1): 51.
- Stumpf JD, et al. (2013). POLG-related disorders. Neurology, 81(18): 1623-1630.
- Tyynismaa H, et al. (2012). Twinkle and mitochondrial disease. Biochimica et Biophysica Acta, 1819(9-10): 850-857.
- Greco V, et al. (2019). Adult-onset mitochondrial myopathy. Journal of Neurology, 266(6): 1380-1387.
- Chinnery PF, et al. (2014). Mitochondrial disease in adults. Annals of Neurology, 76(1): 107-120.